SCHEMBL25812185

SCHEMBL25812185

Cc1cc2[nH]c(C(=O)NC(C)C)cc2cc1F

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 1/20 0.57
EIF4A3 P38919 1/20 0.49
KDM4E B2RXH2 2/20 0.46
ALDH1A1 P00352 2/20 0.46
NPC1 O15118 2/20 0.46
RAB9A P51151 2/20 0.46
PRNP P04156 1/20 0.46
GAA P10253 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
AR P10275 1/20 0.44
MAPT P10636 1/20 0.43
ALPL P05186 1/20 0.42
RXFP1 Q9HBX9 1/20 0.41
TAS1R3 Q7RTX0 1/20 0.41
TAS1R1 Q7RTX1 1/20 0.41
ROCK2 O75116 2/20 0.39
DRD2 P14416 1/20 0.39
ADORA3 P0DMS8 1/20 0.39
ADORA2A P29274 1/20 0.39
ADORA2B P29275 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25758825 0.84 ALOX15 (0.63) ALOX15EIF4A3KDM4EALDH1A1AR
SCHEMBL24740104 0.82 ALOX15 (0.63) ALOX15EIF4A3KDM4EALDH1A1AR
SCHEMBL14205189 0.81 XDH (0.48) ALOX15EIF4A3KDM4EALDH1A1NPC1
SCHEMBL17429451 0.79 EIF4A3 (0.65) EIF4A3KDM4EALDH1A1MAPTKMT2A
SCHEMBL13761503 0.78 MLLT1 (0.61) ALOX15KDM4EALDH1A1NPC1RAB9A
SCHEMBL24019694 0.78 ALOX15 (0.70) ALOX15EIF4A3KDM4EALDH1A1AR
SCHEMBL24019699 0.77 ALOX15 (0.72) ALOX15EIF4A3KDM4EALDH1A1AR
SCHEMBL14845690 0.77 PIN1 (0.62) ALOX15KDM4EALDH1A1NPC1RAB9A
SCHEMBL4041495 0.75 KDM4E (0.63) ALOX15EIF4A3KDM4EALDH1A1NPC1
SCHEMBL832561 0.75 XDH (0.48) ALOX15EIF4A3KDM4EALDH1A1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230212152-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF Pardes Biosciences, Inc. 2023-07-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230212152-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF CTRL, CTSL, CTSV ALOX15 1455/4885EIF4A3 582/4885KDM4E 3122/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.